178 related articles for article (PubMed ID: 20847494)
1. Recent development of molecular-targeted drugs in lung cancer.
Saijo N; Kenmotsu H
Intern Med; 2010; 49(18):1923-34. PubMed ID: 20847494
[TBL] [Abstract][Full Text] [Related]
2. [New biological treatments for lung cancer].
Zalcman G; Richard N; Bergot E
Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Auberger J; Loeffler-Ragg J; Wurzer W; Hilbe W
Curr Cancer Drug Targets; 2006 Jun; 6(4):271-94. PubMed ID: 16848720
[TBL] [Abstract][Full Text] [Related]
4. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.
Takeda M; Nakagawa K
Curr Cancer Drug Targets; 2015; 15(9):792-802. PubMed ID: 26567882
[TBL] [Abstract][Full Text] [Related]
5. Newer opportunities in systemic therapy of lung cancer.
Rajan A; Gutierrez M; Giaccone G
Ann Oncol; 2008 Sep; 19 Suppl 7(Suppl 7):vii31-7. PubMed ID: 18790973
[No Abstract] [Full Text] [Related]
6. [Targeted therapies. New hopes, new challenges].
Barlési F
Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
[No Abstract] [Full Text] [Related]
7. Targeted therapies in gynecologic cancers.
Chon HS; Hu W; Kavanagh JJ
Curr Cancer Drug Targets; 2006 Jun; 6(4):333-63. PubMed ID: 16848724
[TBL] [Abstract][Full Text] [Related]
8. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
Kelly K; Huang C
J Thorac Oncol; 2008 Jun; 3(6):664-73. PubMed ID: 18520811
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
10. Targeting angiogenesis for treatment of NSCLC brain metastases.
Schettino C; Bareschino MA; Rossi A; Maione P; Sacco PC; Colantuoni G; Rossi E; Gridelli C
Curr Cancer Drug Targets; 2012 Mar; 12(3):289-99. PubMed ID: 22229249
[TBL] [Abstract][Full Text] [Related]
11. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
12. Current status on biologic therapies in the treatment of epithelial ovarian cancer.
Han ES; Lin P; Wakabayashi M
Curr Treat Options Oncol; 2009 Apr; 10(1-2):54-66. PubMed ID: 19381822
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies for non-small cell lung cancer: an evolving landscape.
Pal SK; Figlin RA; Reckamp K
Mol Cancer Ther; 2010 Jul; 9(7):1931-44. PubMed ID: 20571071
[TBL] [Abstract][Full Text] [Related]
15. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
16. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
Pérol M
Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154
[No Abstract] [Full Text] [Related]
17. Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer.
Joy AA; Butts CA
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S24-9. PubMed ID: 19362943
[TBL] [Abstract][Full Text] [Related]
18. Perspectives on novel therapies for bronchial carcinoma.
Blackhall F; Papakotoulas PI; Danson S; Thatcher N
Expert Opin Pharmacother; 2005 Jun; 6(7):1157-67. PubMed ID: 15957969
[TBL] [Abstract][Full Text] [Related]
19. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
20. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
